Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis - A one-year prospective study

Pediatric Pulmonology

Volumn 45, Issue 9, 2010, Pages 874-882

  Rozov, Tatiana ^a   De Oliveira, Viviane Ziebell ^b   Santana, Maria Angélica ^c   Adde, Fabíola Villac ^d   Mendes, Rita Heloisa ^e   Paschoal, Ilma Aparecida ^f   Caldeira Reis, Francisco J ^g   Shinzato Higa, Laurinda Yoko ^h   De Castro Toledo Jr , Antonio Carlos ⁱ   Pahl, Márcia ^j   De Abreu E Silva, Fernando ^b   Gramacho, Ana Paula ^c   Della Zuana, Adriana ^d   Pereira, Mônica Corso ^f   Vergara, Alberto Andrade ^g   Folescu, Tânia Wrobel ^h   Ribeiro, Antônio Fernando ^f   Neto, Norberto Ludwig ^k   Oliveira, Andressa Armando ^k   Lidia Alice Torres G G M ^d   Machado Fernandes, Maria Inez ^d   Ferrari, Giesela Fleischer ^l   Chiba, Sonia Maymi ^a   Mauri, Juliana Ferreira ^a   De Castro E Silva, Claudia ^m   Buzinari, Marlene ⁿ   Bedran, Maria Beatriz ⁿ   Camargos, Paulo ⁿ   Bernardino Da Costa, Claudia Lindroneta ^o   Damaceno, Neiva ^p   Martins, Lívia ^p   more..

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c HEOM   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e HB   (Brazil)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g CGP   (Brazil)

^h INSTITUTO OSWALDO CRUZ   (Brazil)

ⁱ Vascular BH Institute   (Brazil)

^j Roche Brasil   (Brazil)

^k HIJG   (Brazil)

^l SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^m HIAS   (Brazil)

ⁿ FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^o FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^p SCM   (Brazil)

more..

Author keywords

Cystic fibrosis; Quality of life; rhDNase; Treatment

Indexed keywords

DORNASE ALFA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY IMAGE; BRAZIL; CAREGIVER; CHILD; CLINICAL TRIAL; CYSTIC FIBROSIS; DIGESTIVE SYSTEM DISEASE; EMOTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SOCIAL ASPECT; STATISTICAL ANALYSIS;

ADOLESCENT; BRAZIL; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; EXPECTORANTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 77957273192     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21267     Document Type: Article

References (40)

1. Cystic Fibrosis Foundation 2007; Annual report, Vol. 2009. Bethesda: Cystic Fibrosis Foundation; 2008.
2. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240.
3. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Jr., Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-969.
4. Orenstein DM, Winnie GB, Altman H. Cystic fibrosis: a 2002 update. J Pediatr 2002;140:156-164.
5. Shah PL, Conway S, Scott SF, Rainisio M, Wildman M, Stableforth D, Hodson ME. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Respiration 2001;68:160-164.
6. Abbott J, Gee L. Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design. Paediatr Drugs 2003;5:41-56. (Pubitemid 36127024)
7. Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 2007;4:378-386.
8. U. S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U. S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79.
9. Quittner A, Buu A, Watrous M, Davis M. Cystic fibrosis questionnaire: a health-related quality of life measure. User manual. English version 1.0. Bethesda: Cystic Fibrosis Foundation; 2000.
10. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch- Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-928.
11. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135:1223-1232.
12. Rozov T, Cunha MT, Nascimento O, Quittner AL, Jardim JR. Linguistic validation of cystic fibrosis quality of life questionnaires. J Pediatr (Rio J) 2006;82:151-156.
13. Quittner A, Watrous M, Modi A, Messer M. Cystic fibrosis questionnaire-revised: a health-related quality of life measure. CD-ROM. English version 2.0; 2004.
14. Cheng B, Chow S. Validity of LOCF. In: Chow S, editor. Encyclopedia of biopharmaceutical statistics, 2nd edition. London: Informa Healthcare; 2003. pp. 1023-1029.
15. Tang L, Song J, Belin TR, Unutzer J. A comparison of imputation methods in a longitudinal randomized clinical trial. Stat Med 2005;24:2111-2128.
16. Cohen J. Statistical power analysis for the behavioral science. New York: Laurence Erlbaum; 1988.
17. Abbott J. Coping with cystic fibrosis. J R Soc Med 2003;43: 42-50.
18. Abbott J, Hart A. Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review. Health Qual Life Outcomes 2005;3:19.
19. American Thoracic Society. Cystic fibrosis, Vol. 2009. New York: American Thoracic Society; 2007.
20. Barrett B, Brown D, Mundt M, Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making 2005;25:250-261.
21. Clarke SA, Eiser C. The measurement of health-related quality of life (QOL) in paediatric clinical trials: a systematic review. Health Qual Life Outcomes 2004;2:66. (Pubitemid 40472017)
22. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 2000;18:419-423.
23. Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol 2003;28:535-545.
24. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005;128:2347-2354.
25. Sawyer MG, Reynolds KE, Couper JJ, French DJ, Kennedy D, Martin J, Staugas R, Ziaian T, Baghurst PA. Health-related quality of life of children and adolescents with chronic illness - a two year prospective study. Qual Life Res 2004;13:1309-1319.
26. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, Thompson S, Bush A, Wallis C. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358:1316-1321.
27. Arrington-Sanders R, Yi MS, Tsevat J, Wilmott RW, Mrus JM, Britto MT. Gender differences in health-related quality of life of adolescents with cystic fibrosis. Health Qual Life Outcomes 2006;4:5.
28. Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Quality of life in cystic fibrosis: the impact of gender, general health perceptions and disease severity. J Cyst Fibros 2003;2:206-213. (Pubitemid 37376499)
29. Patterson JM, Wall M, Berge J, Milla C. Gender differences in treatment adherence among youth with cystic fibrosis: development of a new questionnaire. J Cyst Fibros 2008;7:154-164.
30. Brozek JL, Guyatt GH, Schunemann HJ. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes 2006;4:69.
31. Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006;7:62.
32. Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005;14:285-295.
33. Britto MT, Kotagal UR, Chenier T, Tsevat J, Atherton HD, Wilmott RW. Differences between adolescents' and parents' reports of health-related quality of life in cystic fibrosis. Pediatr Pulmonol 2004;37:165-171. (Pubitemid 38120987)
34. Janse AJ, Sinnema G, Uiterwaal CS, Kimpen JL, Gemke RJ. Quality of life in chronic illness: perceptions of parents and paediatricians. Arch Dis Child 2005;90:486-491.
35. Powers PM, Gerstle R, Lapey A. Adolescents with cystic fibrosis: family reports of adolescent health-related quality of life and forced expiratory volume in one second. Pediatrics 2001; 107:E70.
36. Sawyer MG, Reynolds KE, Couper JJ, French DJ, Kennedy D, Martin J, Staugas R, Baghurst PA. A two-year prospective study of the health-related quality of life of children with chronic illness - the parents' perspective. Qual Life Res 2005;14:395-405.
37. Hodson M, Rainisio M, McKenzie S, et al. The European Epidemiological Registry of cystic fibrosis. Does pulmozyme make any difference? Neth J Med 1999;54:S22-S23.
38. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820.
39. Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess 2001;5:1-157.
40. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire- Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-1618.